A Phase II Study of Everolimus, Leuprolide/Letrozole, and Everolimus/Leuprolide/Letrozole in Patients with Inoperable Fibrolamellar Hepatocellular Carcinoma
[Protocol 11-211] |
Abou-Alfa, Ghassan |
|
A Phase II Study of Everolimus as Second-Line Therapy in the Treatment of Metastatic Renal Cell Carcinoma
[Protocol 11-197] |
Motzer, Robert |
|
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low- Grade and Anaplastic Ependymoma
[Protocol 09-031] |
Omuro, Antonio |
- Brain Tumors, Primary
- Pediatric Brain Tumors
|
A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
[Protocol 10-190] |
Traina, Tiffany |
|
A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
[Protocol 13-022] |
Noy, Ariela |
|
A Phase II Study of Docosahexaenoic Acid (DHA) in Survivors of Triple-Negative Breast Cancer
[Protocol 12-267] |
Hudis, Clifford |
- Breast Cancer
- Survivorship
|
A Phase II Study of DN24-02 as Adjuvant Therapy in Patients with High-Risk HER2-positive Urothelial Cancers
[Protocol 11-163] |
Bajorin, Dean |
|
A Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancers with DDR2 or Inactivating BRAF Mutations
[Protocol 12-163] |
Paik, Paul |
- Lung Cancer
- Lung Cancer, Non-Small Cell
|
A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib
[Protocol 11-030] |
Shukla, Neerav |
- Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myelocytic Leukemia
|
A Phase II Study of Dalantercept to Treat Recurrent or Persistent Endometrial Cancer
[Protocol 12-180] |
Makker, Vicky |
- Endometrial and other Uterine Cancers
|
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma
[Protocol 12-124] |
Chapman, Paul |
|
A Phase II Study of Cyclophosphamide, Topotecan, and Bevacizumab in Patients with Relapsed or Refractory Ewing's Sarcoma and Neuroblastoma
[Protocol 11-183] |
Trippett, Tanya |
- Neuroblastoma
- Primary Bone
- Sarcomas
- Ewing's Sarcoma
- Soft Tissue Sarcoma
|
A Phase II Study of Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
[Protocol 11-005] |
Lee, Nancy |
|
A Phase II Study of Concurrent Intensity-Modulated Radiation Therapy (IMRT),
Paclitaxel, and Pazopanib/Placebo for the Treatment of Anaplastic Thyroid Cancer
[Protocol 10-186] |
Sherman, Eric |
|
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125] |
Omuro, Antonio |
- Lymphoma
- Pediatric Brain Tumors
|
A Phase II Study of CMV-Immune T cells for the Treatment of Cytomegalovirus Infection after Stem Cell Transplantation
[Protocol 12-086] |
O'Reilly, Richard |
- Blood & Marrow Stem Cell Transplantation
|
A Phase II Study of Cixutumumab plus Temsirolimus in Children with Recurrent or Refractory Sarcoma
[Protocol 12-188] |
Wexler, Leonard |
- Primary Bone
- Sarcomas
- Osteosarcoma
- Soft Tissue Sarcoma
|
A Phase II Study of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Ependymoma in Adults
[Protocol 11-146] |
Omuro, Antonio |
- Brain Tumors, Primary
- Pediatric Brain Tumors
|
A Phase II Study of Cabozantinib versus Paclitaxel to Treat Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 13-048] |
Makker, Vicky |
|
A Phase II Study of Cabozantinib in Women with Hormone Receptor-Positive Breast Cancer that Spread to the Bone
[Protocol 12-091] |
Fornier, Monica |
|
